Drug intelligence / Profile preview

N-acetyl-L-phenylalanyl-4-[difluoro(phosphono)methyl]-L-phenylalaninamide

Development stage: Unknown
Modality: Peptides, Small Molecules

Overview

N-acetyl-L-phenylalanyl-4-[difluoro(phosphono)methyl]-L-phenylalaninamide is an experimental small molecule dipeptide composed of two phenylalanine residues, one of which is substituted with a difluorophosphonomethyl group. It belongs to the class of organic compounds known as dipeptides and has not been approved for any therapeutic use. There are no reported clinical trials or approved indications for this compound, and its mechanism of action remains uncharacterized in the literature[1][2]. The compound has been studied primarily in the context of synthetic chemistry and fluorinated amino acid research[3].

Other names: DB07651DB-07651DB 07651

Beyond the preview

Go deeper on N-acetyl-L-phenylalanyl-4-[difluoro(phosphono)methyl]-L-phenylalaninamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-acetyl-L-phenylalanyl-4-[difluoro(phosphono)methyl]-L-phenylalaninamide.

Explore the full profile